Novo Nordisk is investing $4.1 billion to expand its U.S. manufacturing capacity to address the growing demand for its highly sought-after weight-loss-related drugs.  The Danish pharmaceutical manufacturer will also boost its current production investment this year to $6.8 billion, up significantly from $3.9 billion in 2023.With the funds, Novo Nordisk said it plans to add 1.4 million square feet of production space for aseptic manufacturing and finished production processes, which will essentially double t ...